- $266.60m
- $221.94m
- €0.03m
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum
Brief: Inflarx To Announce Topline Data From Phase 2A Clinical Trial Of Inf904 In Hidradenitis Suppurativa And Chronic Spontaneous Urticaria
InflaRx falls after pricing public offering
Brief: Inflarx Says Pricing Of Underwritten Public Offering Of 8.25 Mln Ordinary Shares At $2.00 Per Ordinary Share
Brief: Inflarx Announces Public Offering Of Ordinary Shares And Pre-Funded Warrants
Brief: InflaRx NV Files For Ordinary Shares Offering Of Up To $75 Million
Brief: Inflarx’s Gohibic Selected For First BARDA-Sponsored Clinical Trial To Evaluate Novel Host-Directed Therapeutics For Acute Respiratory Distress Syndrome
InflaRx rises on positive trial results from its anti-inflammatory drug
Brief: InflaRx Announces Positive Topline Results from Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904
Brief: InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
Brief: Inflarx Announces Positive Topline Results From The Single Ascending Dose (Sad) Phase I Study With C5ar Inhibitor Inf904
Brief: Inflarx’S Marketing Authorization Application (Maa) For Vilobelimab
Brief: Inflarx NV Files For Mixed Shelf Of Up To $250 Million – SEC Filing
Brief: InflaRx Announces Commercial Launch Of Gohibic In The US For The Treatment Of Critically Ill Covid-19 Patients
Brief: InflaRx Reports Q1 Results
InflaRx slips on pricing $40 mln share offering